Dr. Michael J. Holtzman received a Technology/Therapeutic Development Award (TTDA) from the Department of Defense for “Preclinical Development of a New Kinase Inhibitor for COPD”. The 3-year award for $3,928,669 will focus on progressive post-viral lung disease, especially relevant to current public health problems with respiratory viral infections including Covid-19, influenza, and other common pathogens. The funding will provide for final preclinical development of a lead compound to achieve approval for clinical trials in human patients.
Dr. Michael J. Holtzman Receives TTDA Award
